Skip to main content
Top
Published in: Clinical Oral Investigations 2/2018

01-03-2018 | Original Article

Influence of bisphosphonates on the adherence and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces

Authors: Fernanda Gonçalves Basso, Taisa N. Pansani, Diana G. Soares, Lais M. Cardoso, Josimeri Hebling, Carlos Alberto de Souza Costa

Published in: Clinical Oral Investigations | Issue 2/2018

Login to get access

Abstract

Objectives

To evaluate the effects of sodium alendronate (SA) and zoledronic acid (ZA), on the adhesion and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces considering cell functions related to an effective mucosal barrier around the implant.

Materials and methods

Cells were seeded onto titanium discs and incubated for 24 h. Then, serum-free DMEM containing selected bisphosphonates (0, 0.5, 1, or 5 μM) was added for 24 and 48 h. Factors related to the achievement of an effective mechanical and immunological barrier—cell adhesion, viability, collagen epidermal growth factor, and immunoglobulin synthesis—were evaluated. Data were analyzed by Kruskal-Wallis and Mann-Whitney tests as well as by ANOVA and Tukey’s tests, (α = 0.05).

Results

The presence of bisphosphonates culminated in lower cell adhesion to the titanium discs, particularly for SA at 5 μM (40%) and ZA at all concentrations (from 30 to 50%, according to increased concentrations). Reduced cell viability occurred after exposing these cells to ZA (40%); however, only 5 μM SA-treated cells had decreased viability (30%). Reduced synthesis of growth factors and collagen was observed when cells were reated with ZA (20 and 40%, respectively), while about 70% of IgG synthesis was enhanced.

Conclusion

Bisphosphonates negatively affected the adhesion and metabolism of oral mucosal cells, and this effect was related to the type of bisphosphonate as well as to concentration and period of treatment.

Clinical relevance

The negative effects of bisphosphonates on oral mucosal cells can hamper the formation of an effective biological seal in osseointegrated implants.
Literature
1.
go back to reference Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978CrossRefPubMed Rogers MJ, Gordon S, Benford HL et al (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978CrossRefPubMed
3.
go back to reference Simon MJK, Niehoff P, Kimming B, Açil Y (2010) Expression profile and synthesis of different collagen types I, II, III and V of human gingiva fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Invest 14:51–58CrossRef Simon MJK, Niehoff P, Kimming B, Açil Y (2010) Expression profile and synthesis of different collagen types I, II, III and V of human gingiva fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Invest 14:51–58CrossRef
4.
go back to reference Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Invest 14:35–41CrossRef Walter C, Klein MO, Pabst A, Al-Nawas B, Duschner H, Ziebart T (2010) Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells. Clin Oral Invest 14:35–41CrossRef
5.
go back to reference Basso FG, Pansani TN, Oliveira CF et al (2013) Cytotoxic effects of zoledronic acid on human epithelial cells and gingival fibroblasts. Braz Dent J 24:551–558CrossRefPubMed Basso FG, Pansani TN, Oliveira CF et al (2013) Cytotoxic effects of zoledronic acid on human epithelial cells and gingival fibroblasts. Braz Dent J 24:551–558CrossRefPubMed
6.
go back to reference Basso FG, Turrioni APS, Hebling J, de Souza Costa CA (2013) Zoledronic acid inhibits human osteoblast activities. Gerontology 59:534–541CrossRefPubMed Basso FG, Turrioni APS, Hebling J, de Souza Costa CA (2013) Zoledronic acid inhibits human osteoblast activities. Gerontology 59:534–541CrossRefPubMed
7.
go back to reference Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis. JADA 136:1658–1668PubMed Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis. JADA 136:1658–1668PubMed
8.
go back to reference Woo S, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761CrossRefPubMed Woo S, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761CrossRefPubMed
9.
go back to reference Diel IJ, Fogelman I, Al-Nawas B et al (2007) Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: is there a diverse relationship of amino and non-aminobisphosphonates? Crit Rev Oncol Hematol 64:198–207CrossRefPubMed Diel IJ, Fogelman I, Al-Nawas B et al (2007) Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: is there a diverse relationship of amino and non-aminobisphosphonates? Crit Rev Oncol Hematol 64:198–207CrossRefPubMed
10.
go back to reference Idris AI, Rojas J, Greis IR, van’t Hof RJ, Ralston SH (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191–201CrossRefPubMed Idris AI, Rojas J, Greis IR, van’t Hof RJ, Ralston SH (2008) Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82:191–201CrossRefPubMed
11.
go back to reference Orriss IR, Key ML, Colston KW, Arnett TR (2008) Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106:109–118CrossRef Orriss IR, Key ML, Colston KW, Arnett TR (2008) Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106:109–118CrossRef
12.
go back to reference Scheper MA, Badros A, Salama AR et al (2009) A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer 17:1553–1557CrossRefPubMed Scheper MA, Badros A, Salama AR et al (2009) A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer 17:1553–1557CrossRefPubMed
13.
go back to reference Ravosa MJ, Ning J, Liu Y, Stack S (2011) Bisphosphonate effects on the behavior of oral epithelial cells and oral fibroblasts. Arch Oral Biol 56:491–498CrossRefPubMed Ravosa MJ, Ning J, Liu Y, Stack S (2011) Bisphosphonate effects on the behavior of oral epithelial cells and oral fibroblasts. Arch Oral Biol 56:491–498CrossRefPubMed
14.
go back to reference Basso FG, Turrioni APS, Soares DG, Bagnato VS, Hebling J, de Souza Costa CA (2014) Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid. Support Care Cancer 22:2741–2748CrossRefPubMed Basso FG, Turrioni APS, Soares DG, Bagnato VS, Hebling J, de Souza Costa CA (2014) Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid. Support Care Cancer 22:2741–2748CrossRefPubMed
15.
go back to reference Migliorati CA, Woo S, Hewson I et al (2009) A systematic review of bisphosphonate osteonecroses (BON) in cancer. Support Care Cancer 18:1099–1106CrossRef Migliorati CA, Woo S, Hewson I et al (2009) A systematic review of bisphosphonate osteonecroses (BON) in cancer. Support Care Cancer 18:1099–1106CrossRef
16.
18.
go back to reference Otto S, Pautke C, Opelz C et al (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68:2837–2845CrossRefPubMed Otto S, Pautke C, Opelz C et al (2010) Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68:2837–2845CrossRefPubMed
19.
go back to reference Madrid C, Sanz M (2009) What impact do systemically administered bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Impl Res 20:87–95CrossRef Madrid C, Sanz M (2009) What impact do systemically administered bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Impl Res 20:87–95CrossRef
20.
go back to reference Javed F, Almas K (2010) Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol 81:479–484CrossRefPubMed Javed F, Almas K (2010) Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol 81:479–484CrossRefPubMed
21.
go back to reference Chadha G, Ahmadieh A, Kumar S, Sedghzadeh PP (2013) Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review. J Oral Implantol 39:510–520CrossRefPubMed Chadha G, Ahmadieh A, Kumar S, Sedghzadeh PP (2013) Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review. J Oral Implantol 39:510–520CrossRefPubMed
22.
go back to reference Taxel P, Ortiz D, Shafer D et al (2014) The relationship between implant stability and bone health markers in post-menopausal women with bisphosphonate exposure. Clin Oral Invest 18:49–57CrossRef Taxel P, Ortiz D, Shafer D et al (2014) The relationship between implant stability and bone health markers in post-menopausal women with bisphosphonate exposure. Clin Oral Invest 18:49–57CrossRef
23.
go back to reference An N, Rausch-fan X, Wieland M, Matejka M, Andrukhov O, Schedle A (2012) Initial attachment, subsequent cell proliferation/viability and gene expression of epithelial cells related to attachment and wound healing in response to different titanium surfaces. Dent Mater 28:1207–1214CrossRefPubMed An N, Rausch-fan X, Wieland M, Matejka M, Andrukhov O, Schedle A (2012) Initial attachment, subsequent cell proliferation/viability and gene expression of epithelial cells related to attachment and wound healing in response to different titanium surfaces. Dent Mater 28:1207–1214CrossRefPubMed
24.
go back to reference Etminan M, Aminzadeh K, Mathew IR, Brophy JM (2008) Use of oral bisphosphonates and risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 35:691–695PubMed Etminan M, Aminzadeh K, Mathew IR, Brophy JM (2008) Use of oral bisphosphonates and risk of aseptic osteonecrosis: a nested case-control study. J Rheumatol 35:691–695PubMed
25.
go back to reference Khan AA, Sándor GK, Dore E et al (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391–1397PubMed Khan AA, Sándor GK, Dore E et al (2008) Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35:1391–1397PubMed
26.
go back to reference Bedogni A, Bettini G, Totola A, Saia G, Nocini PF (2010) Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgey: a case report and literature review. J Oral Maxillofac Surg 68:1662–1666CrossRefPubMed Bedogni A, Bettini G, Totola A, Saia G, Nocini PF (2010) Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgey: a case report and literature review. J Oral Maxillofac Surg 68:1662–1666CrossRefPubMed
27.
go back to reference Assael LA (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 67:35–43CrossRefPubMed Assael LA (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 67:35–43CrossRefPubMed
28.
go back to reference Body JJ, Mancini I (2002) Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10:399–407CrossRefPubMed Body JJ, Mancini I (2002) Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10:399–407CrossRefPubMed
29.
30.
go back to reference Patidar K, Parwani RN, Wanjari SP (2011) Correlation of salivary and serum IgG, IgA levels wih total protein in oral submucous fibrosis. J Oral Sci 53:97–102CrossRefPubMed Patidar K, Parwani RN, Wanjari SP (2011) Correlation of salivary and serum IgG, IgA levels wih total protein in oral submucous fibrosis. J Oral Sci 53:97–102CrossRefPubMed
31.
go back to reference Tilakaratne WM, Klinikowki MF, Saku T, Peters TJ, Warnakulasuriya S (2006) Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42:561–568CrossRefPubMed Tilakaratne WM, Klinikowki MF, Saku T, Peters TJ, Warnakulasuriya S (2006) Oral submucous fibrosis: review on aetiology and pathogenesis. Oral Oncol 42:561–568CrossRefPubMed
Metadata
Title
Influence of bisphosphonates on the adherence and metabolism of epithelial cells and gingival fibroblasts to titanium surfaces
Authors
Fernanda Gonçalves Basso
Taisa N. Pansani
Diana G. Soares
Lais M. Cardoso
Josimeri Hebling
Carlos Alberto de Souza Costa
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 2/2018
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-017-2167-2

Other articles of this Issue 2/2018

Clinical Oral Investigations 2/2018 Go to the issue